1. Home
  2. SMID vs CRDF Comparison

SMID vs CRDF Comparison

Compare SMID & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$35.11

Market Cap

151.1M

Sector

Industrials

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.68

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
CRDF
Founded
1960
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.1M
130.7M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
SMID
CRDF
Price
$35.11
$1.68
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
6.1K
705.3K
Earning Date
04-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
27.37
EPS
2.36
N/A
Revenue
$93,446,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.92
N/A
Revenue Growth
19.03
49.61
52 Week Low
$25.60
$1.48
52 Week High
$43.62
$4.56

Technical Indicators

Market Signals
Indicator
SMID
CRDF
Relative Strength Index (RSI) 63.36 49.38
Support Level $35.80 $1.51
Resistance Level $36.89 $1.68
Average True Range (ATR) 1.32 0.09
MACD 0.26 -0.00
Stochastic Oscillator 100.00 37.52

Price Performance

Historical Comparison
SMID
CRDF

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: